Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "women’s-health"

16 News Found

Cosette Pharmaceuticals acquires Intrarosa from Endoceutics
News | June 09, 2023

Cosette Pharmaceuticals acquires Intrarosa from Endoceutics

Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product


Dr. Reddy's Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolio
News | March 01, 2023

Dr. Reddy's Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolio

The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.


ACI Hospitals celebrates the spirit of women with their new campaign ‘WOWMOM’
Biotech | May 06, 2022

ACI Hospitals celebrates the spirit of women with their new campaign ‘WOWMOM’

The campaign aims to promote women’s health and wellness and urge them to visit the hospital for key medical check-ups


Organon declares paid time off for all employees on International Women’s Day
News | March 08, 2022

Organon declares paid time off for all employees on International Women’s Day

As the Covid-19 pandemic continues to have a disproportionate impact on women, Organon issues a call to action for other leaders to create opportunities to focus on women’s health


Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s
Biotech | February 21, 2022

Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s

Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company


Lupin receives U.S. FDA approval for HIV-1 drug
Pharma | June 08, 2021

Lupin receives U.S. FDA approval for HIV-1 drug

Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021